In a list of gene-editing companies jotted down by your average CRISPR enthusiast, MilliporeSigma likely wouldn’t appear. Sangamo, sure. The numerous commercial spinoff companies from the Broad Institute and the University of California, certainly.
But MilliporeSigma has at least one patent that it believes every company applying the technology will need to license — and some companies are already doing that.
MilliporeSigma, a subsidiary of Merck KGaA of Darmstadt, Germany, since 2010 — which is not related to or affiliated with a certain New Jersey-based major pharmaceutical company — is the product of the largest acquisition in the parent company’s history. Finalized in 2015, the $17 billion acquisition of Sigma-Aldrich created something closer to one-stop shopping for life science equipment and materials.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect